Castle Biosciences Inc. (CSTL) Tops Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Castle Biosciences Announces First Quarter 2020 Results
May 11, 2020 4:05 PM EDT
Q1 2020 DecisionDx-Melanoma test report volume increased 42% compared to Q1 2019
Q1 2020 revenues of $17.4 million, compared to $8.7 million in Q1 2019, an increase of 100%
Operating cash flow for Q1 2020 was $(0.3) million
Cash and cash equivalents as of March 31, 2020, totaled $98.7 million
Company suspends 2020 revenue guidance due to COVID-19
Conference call and webcast today at 4:30 p.m. ET
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the... More
